Serum NRG1 levels were significantly reduced across all patient groups (RRMS, SPMS, MS, and NMO) compared to healthy controls, with the most significant decrease observed in NMO patients (Fig. 1A). This evidence concerns the gene NRG1 and secondary progressive multiple sclerosis.